A trial of buprenorphine/naloxone (Bup/Nx) showed no evidence that the medicine was associated with liver damage. The drug gave results similar to those of methadone. The study data indicate that although most patients can be treated safely with either methadone or Bup/Nx without major concern for liver injury, clinicians are advised to continue to monitor the liver health of their patients who are on methadone or Bup/Nx therapy.
Microneedles are an innovative technique for delivering medications through the skin, a route that could particularly benefit patients receiving naltrexone therapy for opioid and alcohol dependence. Researchers have found a way to use the transdermal technique to deliver a single treatment of naltrexone that lasts for 7 days.
Soluble-film preparations of buprenorphine suppressed heroin abusers’ withdrawal symptoms with no serious side effects in a recent clinical trial. They dissolved more rapidly in the mouth than the pill form of the medication, providing faster relief.
Describes findings from two randomized clinical trials showing that treatment with multidimensional family therapy resulted in fewer drug-related problems than treatment with cognitive behavior therapy.
Clinical trials of N-acetylcysteine to help people recovering from drug abuse avoid relapse have demonstrated only moderate efficacy. New NIDA-supported research shows that while a low dose of the medication activates receptors associated with lowered drug-seeking behavior, a higher dose appears to activate receptors associated with increased drug-seeking behavior. The result suggests that a medication or combination of medications that stimulate the receptor GluR2/3 and block mGluR5 may work better than N-acetylcysteine alone.